📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-29 09:22
709 analysed today
709
Today
133,598
All-time analysed
40,124
Positive
6,284
Negative
79,370
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
26 announcements match the current filters (relevance ≥ 5).
Godavari Biorefineries Receives ₹18.13 Cr GST Show Cause Notice in Karnataka
Godavari Biorefineries has received a Show Cause Notice on August 28, 2026, from the Commercial Tax Officer (Enforcement), DGSTO, Jamkhandi, Karnataka, for the tax period 2022-23. The total demand amounts to ₹18.13 crore, comprising ₹10.57 crore in core GST demand, ₹6.50 crore in interest, and ₹1.06 crore in penalties under Section 73 of the CGST/KGST Act. The notice alleges short payment and ineligible Input Tax Credit (ITC) utilization. The company is evaluating the financial impact and plans to file replies and appeals as advised.
Confidence: HIGH
What changedThe Karnataka tax authority issued a ₹18.13 crore SCN alleging ineligible ITC utilization during FY 2022-23.
Why it mattersWhile the ₹18.13 crore claim is small relative to annual revenue (~0.9% of TTM revenue of ₹2,013 Cr), it is material compared to FY26 PAT (₹3.25 Cr) if upheld in adjudication.
Total Demand with Interest & Penalty: Rs. 18,12,85,079Base Tax Demand: Rs. 10, 57, 05,586Interest Demand: Rs. 6,50,08,935Penalty: Rs. 1,05,70,559Total Demand vs TTM Revenue: ~0.90%
📅 Short termCompany will file a legal reply/appeal; at the show-cause stage, immediate operational or cash flow impact is limited.
📈 Long termIf finalized into an adverse demand order without appellate relief, it could create cash outflows and hit net margins.
⚠ Risk flags
- Potential liability of up to ₹18.13 Cr if legal appeals fail
- Protracted tax dispute proceedings
Key Highlights
Total demand of ₹18,12,85,079 issued under Section 73(1) of the CGST/KGST Act, 2017.
Core tax demand of ₹10,57,05,586 includes IGST (₹5.13 Cr), CGST (₹2.69 Cr), SGST (₹2.69 Cr), and Cess (₹0.06 Cr).
Applicable interest assessed at ₹6,50,08,935 alongside a penalty of ₹1,05,70,559.
Notice pertains to alleged short payment and ineligible ITC availed/utilised during FY 2022-23.
👀 What to Watch
Track the outcome of the company's reply/appeal submissions and monitor whether any tax provisions or deposits are reflected in upcoming quarterly financials.
GST Show Cause Notice of ₹17.02 Cr Received for ENA Supplies to KSBCL
Godavari Biorefineries has received a Show Cause Notice from the Assistant Commissioner of Central GST, Belagavi, Karnataka, demanding ₹17.02 Cr. The dispute pertains to the alleged non-payment of GST on the supply of Extra Neutral Alcohol (ENA) to Karnataka State Beverages Corporation Ltd. (KSBCL) between FY2021-22 and October 2024. The demand consists of ₹8.51 Cr CGST and ₹8.51 Cr SGST under Section 74(1) of the CGST/SGST Act. The company is examining the notice and plans to submit replies and appeals as advised.
Confidence: HIGH
What changedCentral GST authorities have issued a ₹17.02 Cr tax demand notice regarding past ENA supplies categorized by the company as exempt.
Why it mattersWhile representing ~0.85% of TTM revenue (₹2,013 Cr), the ₹17.02 Cr demand exceeds the entire FY26 net profit (₹3.25 Cr), posing potential cash outflow risks if adjudicated adversely.
Total GST Demand: ₹17,02,29,150CGST Claim: ₹8,51,14,575SGST Claim: ₹8,51,14,575Demand vs TTM Revenue: ~0.85%Period under dispute: 2021-22 to October 2024
📅 Short termThe announcement introduces legal overhang; near-term focus will be on the company's legal response and whether any pre-deposit is required.
📈 Long termENA taxation has historically been an industry-wide legal issue between State Excise and GST; final clarity will depend on judicial outcomes across the sector.
⚠ Risk flags
- Tax liability crystallisation could impact liquidity and net profitability.
- Potential interest and penalty exposure if the demand is upheld.
Key Highlights
Total GST demand of ₹17,02,29,150 (~₹17.02 Cr) issued by CGST Audit, Belagavi.
Split equally into CGST of ₹8,51,14,575 and SGST of ₹8,51,14,575.
Dispute relates to ENA supplies treated as 'exempted supply' to KSBCL from 2021-22 to October 2024.
Demand of ₹17.02 Cr is material relative to FY26 net profit of ₹3.25 Cr (~0.85% of TTM revenue).
👀 What to Watch
Track the company's formal reply to the Show Cause Notice and any subsequent adjudication order or appellate tribunal filings.
Godavari Biorefineries Commissions 200 KLPD Distillery; Plans ₹25 Cr Chemical Expansion
Godavari Biorefineries reported Q1 FY27 revenue of ₹557.9 Cr, up 4.6% YoY, though EBITDA margins contracted to 0.5% from 1.2% due to high inventory carrying costs. A major milestone was the commissioning of a 200 KLPD grain-based distillery, bringing total capacity to 800 KLPD and providing feedstock flexibility. The company announced a fresh ₹25 Cr investment for debottlenecking its bio-based chemicals segment, which saw 19.4% revenue growth. Additionally, the company is moving into clinical trials for an anticancer molecule in Q3 FY27 after securing a Japanese patent.
Confidence: HIGH
What changedThe company has transitioned to an 800 KLPD distillery capacity with dual-feedstock (grain and cane) capability and is increasing its focus on high-margin bio-based chemicals.
Why it mattersThe shift to a grain-based distillery reduces dependence on cyclical sugarcane availability and government ethanol pricing for cane-based fuel, while the chemical expansion targets higher-margin specialty markets.
New Distillery Capacity: 200 KLPDTotal Distillery Capacity: 800 KLPDChemical Debottlenecking Capex: ₹25 CrCapex vs Market Cap: ~2.05%Q1 FY27 Revenue: ₹557.9 CrBio-chemical EBITDA Growth: 53%
📅 Short termThe market may focus on the weak Q1 EBITDA margin of 0.5%, but the commissioning of the new distillery provides a positive operational catalyst for the upcoming quarters.
📈 Long termThe integrated biorefinery model and expansion into pharmaceutical R&D represent a structural shift toward higher-value products, potentially reducing the volatility of the core sugar business.
⚠ Risk flags
- Elevated inventory carrying costs
- Regulatory shifts in ethanol blending policy
- Agroclimatic risks affecting sugarcane yields
Key Highlights
Commissioned a 200 KLPD grain-based distillery at Sameerwadi, increasing total distillery capacity to 800 KLPD.
Bio-based chemicals segment delivered 19.4% YoY revenue growth and a 53% increase in EBITDA.
Announced ₹25 Cr new capex for debottlenecking specialty chemical capacity to meet growing export and domestic demand.
Secured a Japanese patent for a novel anticancer molecule with clinical trials expected to start in Q3 FY27.
Allocated ₹20 Cr over the next 30-33 months for drug discovery and safety trials.
👀 What to Watch
Monitor the margin improvement from the new 200 KLPD grain-based distillery and the commencement of clinical trials for the pharmaceutical segment in Q3 FY27.
Godavari Biorefineries Secures European Patent for Oncology Pharmaceutical Composition
Godavari Biorefineries has been granted a patent (EP4404920) by the European Patent Office for a novel pharmaceutical composition targeting breast and prostate cancers. The invention focuses on enhancing the solubility and bioavailability of anti-cancer compounds for oral administration. This development aligns with the company's strategic shift toward high-value specialty chemicals and pharmaceuticals to diversify from its core sugar and ethanol business, which currently accounts for 67% of revenue. While the TTM PAT stands at a thin Rs 3 Cr, successful commercialization of such IP could significantly impact long-term margins.
Confidence: HIGH
What changedThe company has transitioned from a patent application to a granted patent status in the European jurisdiction for its oncology research.
Why it mattersIt validates the company's R&D capabilities in the pharmaceutical space, providing a foundation for higher-margin revenue streams that are less dependent on sugarcane cycles and government ethanol pricing.
Patent Number: EP4404920Grant Date: 15.07.2026TTM Revenue: Rs 1988 CrTTM PAT: Rs 3 CrSugar/Distillery Revenue Mix: 67%
📅 Short termThe news is sentimentally positive for the stock, showcasing R&D depth, though no immediate impact on earnings is expected.
📈 Long termThis strengthens the company's oncology-focused IP portfolio, which is critical for its long-term goal of becoming a diversified biorefinery with high-margin pharmaceutical exports.
⚠ Risk flags
- Commercialization risk
- Long gestation periods for drug development
- High R&D costs relative to current low profitability
Key Highlights
European Patent Office granted patent EP4404920 on July 15, 2026, for oncology-focused compositions.
The patent covers novel anti-cancer compounds combined with solubilising agents for improved oral bioavailability.
Targets high-value therapeutic areas including breast and prostate cancer management.
Supports the company's expansion strategy following the USD 350,000 acquisition of Sathgen Therapeutics in November 2025.
Aims to improve the current operating profit margin (OPM) of 6.4% by moving into high-margin pharmaceutical IP.
👀 What to Watch
Investors should monitor the company's progress in clinical trials or potential licensing deals for this IP, as well as the revenue contribution from the 'Specialty Chemicals' segment in future quarterly reports.
800 KLPD Total Capacity Reached; Q1 Revenue Up 4.9% to ₹559.9 Cr Amidst Margin Pressure
Godavari Biorefineries reported a 4.9% YoY increase in total income to ₹559.9 Cr for Q1 FY27, though EBITDA margins contracted to 0.5% resulting in a net loss of ₹19.3 Cr. The Bio-based Chemicals segment showed strong growth with a 53% YoY increase in EBITDA to ₹19.2 Cr, reflecting a shift toward higher-value products. A key milestone was the commissioning of a 200 KLPD grain-based distillery, bringing total capacity to 800 KLPD and enabling dual-feedstock flexibility. Additionally, the company secured a Japanese patent for a novel anti-cancer molecule, signaling a pivot toward high-value drug discovery.
Confidence: HIGH
What changedThe company transitioned to a dual-feedstock model with the commissioning of a 200 KLPD grain-based distillery and increased its revenue contribution from Bio-based Chemicals to 30%.
Why it mattersThis diversification reduces reliance on the cyclical sugar business and targets higher-margin pharmaceutical and specialty chemical markets, aiming for more stable cash flows.
Q1 FY27 Total Income: ₹559.9 CrTotal Distillery Capacity: 800 KLPDBio-based Chemicals EBITDA Growth: 53%Q1 Net Loss: ₹19.3 CrIncremental Capex: ₹25 CrCapex vs Market Cap: ~2.04%
📅 Short termThe stock may face pressure in the near term due to the reported net loss and thin EBITDA margins of 0.5% despite the revenue growth.
📈 Long termThe expansion to 800 KLPD and the shift toward specialty chemicals (targeting ₹240 Cr quarterly sales by Q3 FY28) represent a structural move toward a higher-margin biorefinery model.
⚠ Risk flags
- Continued quarterly losses
- High debt of ₹525 Cr relative to TTM PAT
- Agroclimatic risks affecting sugarcane yields
Key Highlights
Commissioned 200 KLPD grain-based distillery, increasing total distillery capacity to 800 KLPD
Bio-based Chemicals revenue grew 19.8% YoY to ₹168.7 Cr with EBITDA margins expanding to 11.4%
Total Income for Q1 FY27 stood at ₹559.9 Cr compared to ₹534.0 Cr in Q1 FY26
Net Loss widened to ₹19.3 Cr from a loss of ₹16.0 Cr in the previous year's quarter
Planned incremental capex of ₹25 Cr for further debottlenecking in the specialty chemicals segment
👀 What to Watch
Monitor the utilization levels of the newly commissioned 200 KLPD grain distillery and its ability to offset sugarcane seasonality. Track the progress of CDSCO efficacy trials for the anti-cancer molecule as a potential long-term value driver.
Q1 FY27: Godavari Biorefineries Revenue up 5% to ₹560 Cr; Net Loss Widens to ₹19.3 Cr
Godavari Biorefineries reported a 4.8% YoY increase in total income to ₹559.9 Cr for Q1 FY27, yet consolidated net losses widened to ₹19.3 Cr from ₹16.0 Cr in Q1 FY26. EBITDA saw a sharp decline of 60% YoY to ₹2.6 Cr, primarily due to industry headwinds and an 11.4% rise in finance costs to ₹13.9 Cr. A key operational milestone was the commissioning of a 200 KLPD grain-based distillery, increasing total ethanol capacity to 800 KLPD. The revenue mix shifted significantly, with Bio-based Chemicals now contributing 39% of revenue compared to 26% in the previous year.
Confidence: HIGH
What changedThe company has transitioned to a higher ethanol capacity (800 KLPD) and increased its revenue reliance on bio-based chemicals while facing widening losses.
Why it mattersThe widening loss despite revenue growth highlights margin pressure and high debt servicing costs (₹13.9 Cr interest vs ₹2.6 Cr EBITDA), making the ramp-up of the new capacity critical for survival.
Total Income (Q1 FY27): ₹559.9 CrNet Loss (Q1 FY27): ₹19.3 CrEBITDA: ₹2.6 CrEthanol Capacity: 800 KLPDFinance Costs: ₹13.9 CrRevenue vs TTM Revenue: 28.1%
📅 Short termThe stock may face pressure due to the widening net loss and extremely thin EBITDA margins reported for the quarter.
📈 Long termThe structural shift toward bio-based chemicals and pharmaceutical R&D offers a potential re-rating path if the company can manage its debt and stabilize sugar/ethanol margins.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High finance costs relative to operating profit
- Continued quarterly losses
- Regulatory risks in ethanol blending and sugar exports
Key Highlights
Total income grew 4.8% YoY to ₹559.9 Cr, representing approximately 28% of TTM revenue.
Net loss widened to ₹19.3 Cr from a loss of ₹16.0 Cr in the same quarter last year.
Ethanol capacity expanded by 33% to 800 KLPD following the commissioning of a new 200 KLPD grain-based unit.
Finance costs rose 11.4% YoY to ₹13.9 Cr, impacting the bottom line.
Bio-based Chemicals segment revenue share increased to 39% from 26% YoY, showing a pivot toward higher-value products.
👀 What to Watch
Investors should monitor the capacity utilization of the newly commissioned 200 KLPD distillery and the progress of CDSCO clinical trials for the company's anti-cancer molecule starting in Q3 FY27.
Q1 Net Loss Widens to ₹19.32 Cr Despite 4.6% Revenue Growth to ₹557.88 Cr
Godavari Biorefineries reported a consolidated net loss of ₹19.32 Cr for Q1 FY27, widening from a loss of ₹16.02 Cr in the year-ago period. Revenue from operations grew 4.6% YoY to ₹557.88 Cr, supported by a strong performance in the Bio-based Chemicals segment which posted an operating profit of ₹14.01 Cr. However, the core Sugar and Distillery segments struggled, reporting operating losses of ₹16.82 Cr and ₹1.77 Cr respectively. High finance costs of ₹13.93 Cr continue to weigh on the bottom line, representing approximately 2.5% of quarterly revenue.
Confidence: HIGH
What changedThe company reported its Q1 FY27 results, showing a widening net loss despite marginal revenue growth, primarily due to operating losses in the sugar and distillery segments.
Why it mattersThe results highlight the company's heavy reliance on its chemical segment to offset the inherent seasonality and current weakness in its sugar and distillery operations.
Revenue (Q1 FY27): ₹557.88 CrNet Loss (Q1 FY27): ₹19.32 CrBio-based Chemicals Segment Profit: ₹14.01 CrFinance Costs: ₹13.93 CrRevenue vs TTM Revenue: 28.06%
📅 Short termThe widening loss and operating losses in core segments are likely to put downward pressure on the stock price in the near term.
📈 Long termThe structural shift toward high-value bio-based chemicals is positive, but long-term value depends on stabilizing sugar margins and reducing the ₹525 Cr debt pile.
⚠ Risk flags
- Seasonality of sugar business impacting quarterly consistency
- Operating losses in the distillery segment
- High finance costs relative to net profitability
Key Highlights
Consolidated Net Loss widened to ₹19.32 Cr from ₹16.02 Cr in the same quarter last year
Revenue from operations increased by 4.6% YoY to ₹557.88 Cr
Bio-based Chemicals segment profit grew to ₹14.01 Cr, up from ₹9.06 Cr YoY
Sugar segment reported an operating loss of ₹16.82 Cr on revenue of ₹255.32 Cr
Finance costs remained high at ₹13.93 Cr compared to ₹15.30 Cr in Q1 FY26
👀 What to Watch
Investors should monitor the scale-up of the Bio-based Chemicals segment and the company's ability to reduce debt, as finance costs are a significant drag on the thin TTM PAT of ₹3 Cr.
Godavari Biorefineries Adds 200 KLPD Grain-Based Distillery Capacity for Rs 130 Cr
Godavari Biorefineries has commenced a new 200 KLPD corn/grain-based distillery at its Sameerwadi unit, marking a strategic shift toward dual-feedstock capability. The project involved an investment of approximately Rs 130 Cr, which represents nearly 10% of the company's market capitalization and 17% of its net worth. This expansion increases total distillery capacity by 33% from the existing 600 KLPD. While current capacity utilization is low at 41%, the move is designed to ensure year-round ethanol production and mitigate risks associated with sugarcane availability.
Confidence: HIGH
What changedThe company has transitioned from a sugarcane-only distillery model to a dual-feedstock model by adding grain-based ethanol production capacity.
Why it mattersThis diversification reduces the company's vulnerability to sugarcane crop cycles and regulatory restrictions on sugar-to-ethanol conversion, positioning it better for India's Ethanol Blending Program.
Capacity Addition: 200 KLPDInvestment Amount: Rs 130 CrInvestment vs Market Cap: ~9.8%Investment vs Net Worth: ~16.8%Existing Capacity Utilization: 41%
📅 Short termThe commencement is a positive milestone that may improve sentiment, though the immediate financial impact depends on the ramp-up speed of the new unit.
📈 Long termThe dual-feedstock capability is structurally significant for a biorefinery, providing a hedge against agroclimatic risks and volatile sugar prices over the coming years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Low current capacity utilization (41%)
- High debt levels (Rs 525 Cr) relative to thin profitability
- Raw material price volatility for corn/grains
Key Highlights
Commenced 200 KLPD grain-based distillery capacity at the Sameerwadi Unit on June 29, 2026
Total investment for the expansion is approximately Rs 130 Cr, funded via internal accruals and debt
Existing distillery capacity stands at 600 KLPD with a current utilization rate of 41%
The addition represents a 33% increase in total distillery capacity to 800 KLPD
Strategic shift to dual-feedstock (cane and grain) to ensure resilient production during climate disruptions
👀 What to Watch
Monitor the utilization levels of the new grain-based capacity and its impact on the company's thin TTM PAT of Rs 3 Cr. Investors should watch for margin improvements resulting from a more consistent feedstock supply and the 2G ethanol projects mentioned in the growth strategy.
Godavari Biorefineries Secures Japanese Patent for Cancer Treatment Compound
Godavari Biorefineries Limited has been granted a patent (No. 7869786) by the Japanese Patent Office for a novel compound, 5-HYDROXY-1,4-NAPHTHALENEDIONE, used in cancer treatment. The patent, registered on May 26, 2026, covers compounds that inhibit cancer stem cells with specific efficacy against breast and prostate cancer. This intellectual property milestone validates the company's R&D efforts in high-value specialty chemicals and pharmaceutical intermediates. The original application for this patent was filed on October 26, 2021.
Key Highlights
Japanese Patent Office granted Patent No. 7869786 for cancer treatment applications.
The patent covers 5-HYDROXY-1,4-NAPHTHALENEDIONE, targeting cancer and cancer stem cells.
Demonstrated significant efficacy against major cancer types including breast and prostate cancer.
The patent was officially registered on May 26, 2026, following a 2021 filing.
Strengthens the company's intellectual property portfolio in the global pharmaceutical research space.
👀 What to Watch
Investors should view this as a long-term positive for the company's valuation in the specialty chemicals and biotech sectors. Monitor future announcements regarding the commercialization or licensing of this patent to gauge direct revenue impact.
Godavari Biorefineries FY26 PAT Turns Positive at ₹3.5 Cr; Q4 EBITDA Margin Hits 16.2%
Godavari Biorefineries reported a financial turnaround in FY26, posting a Profit After Tax (PAT) of ₹3.5 crores compared to a loss in FY25. Total income grew 6% YoY to ₹2,000.2 crores, while EBITDA rose 15.8% to ₹139.3 crores. The company significantly improved its capital structure, reducing finance costs by 32% to ₹49.1 crores following a ₹240 crore debt repayment. Operational highlights include record cane crushing of 2.5 million tons and a strategic shift toward specialty chemicals, which now contribute 61% of the bio-based segment revenue.
Key Highlights
FY26 total income reached ₹2,000.2 crores with a turnaround PAT of ₹3.5 crores.
Achieved highest-ever cane crushing of 2.5 million tons in the 2025-26 season.
Finance costs decreased by 32% YoY to ₹49.1 crores due to significant debt reduction.
Specialty chemicals share in the bio-based segment increased to 61% from 58% YoY.
New 200 KLPD grain-based distillery expected to commission by June 2026, adding 60 million liters capacity.
👀 What to Watch
Investors should view the debt reduction and the shift toward high-margin specialty chemicals as strong indicators of long-term value creation. Monitor the successful commissioning of the new distillery in June 2026 as a key growth catalyst for the ethanol segment.
Godavari Biorefineries Receives 20-Year Patent for Branched Alcohol Production Process
Godavari Biorefineries has been granted an Indian patent (No. 590470) for a safe and cost-effective process for the production of branched alcohols. The patent is valid for a term of 20 years, effective retrospectively from June 2, 2020. This grant strengthens the company's intellectual property moat within the bio-based specialty chemicals segment. Such innovations are expected to enhance production efficiency and competitive positioning in the global chemicals market.
Key Highlights
Indian Patent Office granted Patent No. 590470 for a process to produce branched alcohols.
The patent provides protection for a 20-year term starting from June 2, 2020.
The invention focuses on a safe, economic, and cost-effective production method.
Strengthens the company's IP portfolio in the high-value bio-based specialty chemicals sector.
👀 What to Watch
Investors should view this as a positive long-term development for the company's R&D capabilities and margin potential. Monitor for future updates on the commercial scaling of this patented technology.
Godavari Biorefineries FY26 EBITDA Rises 15.8% to ₹139.3 Cr; Debt Reduced by ₹240 Cr
Godavari Biorefineries reported a steady FY26 with total income growing 6% YoY to ₹2,000.2 Crs and EBITDA increasing 15.8% to ₹139.3 Crs. A significant highlight is the 31.6% reduction in finance costs following a ₹240 Crs debt repayment, which has strengthened the balance sheet. The company is diversifying its ethanol feedstock with a new 200 KLPD grain-based distillery expected by June 2026. Additionally, its specialty chemicals segment now contributes 61% of chemical revenues, and the company is venturing into high-value drug discovery with a CDSCO filing expected in Q2 FY26.
Key Highlights
FY26 Total Income grew 6.0% YoY to ₹2,000.2 Crs, while EBITDA rose 15.8% to ₹139.3 Crs.
Finance costs decreased by 31.6% YoY to ₹49.1 Crs following a ₹240 Crs debt repayment.
Ethanol segment revenue increased 12.6% YoY to ₹658.6 Crs, with 98 million liters sold in FY26.
Specialty chemicals now account for 61% of the bio-based chemicals revenue mix, up from 58% in FY25.
New 200 KLPD grain-based distillery to be commissioned by June 2026, adding 60 million liters of annual capacity.
👀 What to Watch
Investors should monitor the successful commissioning of the new grain-based distillery in June 2026 and the progress of the oncology drug filing in Q2 FY26. The company's focus on debt reduction and high-margin specialty chemicals makes it a strong candidate for long-term growth in the bio-refinery space.
Godavari Biorefineries Q4 PAT Falls 26.5% YoY to ₹52.9 Cr; FY26 Returns to Profit
Godavari Biorefineries reported a 26.5% YoY decline in Q4 FY26 PAT to ₹52.9 crore, primarily due to elevated feedstock costs impacting the sugar and ethanol segments. However, the company achieved a significant full-year turnaround, posting a net profit of ₹3.5 crore in FY26 compared to a loss of ₹23.4 crore in FY25. Revenue for the full year grew to ₹2,000.2 crore, supported by record cane crushing of 2.5 million tonnes and strong growth in the Jivana consumer brand.
Key Highlights
Q4 FY26 PAT stood at ₹52.9 Cr, down 26.5% YoY but showing a 540.8% recovery on a QoQ basis.
Full-year FY26 revenue reached ₹2,000.2 Cr, a growth from ₹1,886.9 Cr in FY25.
Achieved highest-ever cane crushing of 2.5 Mn tonnes during the 2025-26 season.
Jivana consumer brand revenue increased to ₹129 Cr in FY26 from ₹108 Cr in FY25.
EBITDA margins for Q4 FY26 compressed to 16.2% from 20.7% YoY due to industry-wide feedstock cost pressures.
👀 What to Watch
Investors should monitor the company's progress in scaling its high-margin specialty chemicals and the impact of ethanol blending policies on future margins. The annual turnaround is positive, but the volatility in raw material costs remains a key risk factor to watch.
Godavari Biorefineries Approves FY26 Results; Achieves Record 25.18 Lakh MT Cane Crushing
Godavari Biorefineries has approved its audited financial results for the fiscal year ended March 31, 2026, alongside a significant series of leadership re-appointments. The company reported a major operational milestone, achieving its highest-ever cane crushing performance of 25.18 lakh MT during the 2025-26 season. To ensure strategic continuity, the board re-appointed the Managing Director, Executive Director, and other key board members for terms ranging from three to five years. The statutory auditors have issued an unmodified opinion on the financial statements, confirming reporting integrity.
Key Highlights
Achieved record cane crushing of 25.18 lakh MT in the 2025-26 season, surpassing the previous year's 24.65 lakh MT.
Re-appointed Samir S. Somaiya as Managing Director for a three-year term effective April 1, 2027.
Approved audited standalone and consolidated financial results for the year ended March 31, 2026, with an unmodified audit opinion.
Appointed Dinesh Sharma as Whole Time Director, bringing 29 years of sugar technology and operational expertise.
Re-appointed multiple directors including Dr. Sangeeta Srivastava and Nitin Mehta to maintain leadership stability.
👀 What to Watch
Investors should analyze the full financial statement to see how the record crushing volumes impacted revenue and margins. The management continuity and operational records suggest a strong foundation for future growth in the ethanol and biorefinery segments.
CARE Reaffirms Godavari Biorefineries' Long-Term Rating at 'BBB+; Stable'
CARE Ratings has reaffirmed Godavari Biorefineries' long-term rating at 'CARE BBB+; Stable' for bank facilities worth ₹653.83 crore. Despite an 11% growth in Total Operating Income to ₹1,870.25 crore in FY25, the company's PBILDT margin contracted to 5.55% due to higher sugarcane prices and ethanol production restrictions. While overall gearing improved to 0.94x following IPO proceeds, the Total Debt/PBILDT ratio remains high at 4.93x, exceeding the preferred threshold of 3.5x. Investors should monitor the upcoming 200 KLPD grain-based distillery expected to commercialize in Q1FY27 for potential margin recovery.
Key Highlights
CARE reaffirmed 'BBB+; Stable' for ₹653.83 crore long-term facilities and 'A2' for ₹97 crore short-term facilities.
FY25 Total Operating Income grew 11% YoY to ₹1,870.25 crore, though PBILDT margins fell 238 bps to 5.55%.
Overall gearing improved significantly to 0.94x as of March 2025 from 2.79x in the previous year due to IPO-led debt repayment.
Net loss for 9MFY26 narrowed to ₹49 crore from a ₹95 crore loss in 9MFY25, despite a ₹34 crore exceptional expense.
Company is setting up a 200 KLPD grain-based distillery scheduled for commercialization in Q1FY27 to diversify feedstock.
👀 What to Watch
Investors should maintain a neutral outlook as the rating reaffirmation provides credit stability, but keep a close watch on the high debt-to-EBITDA ratio. The successful commissioning of the grain-based distillery in 2026 will be the primary catalyst for improving operational margins.
Godavari Biorefineries Secures Japanese Patent for Antiviral Infection Treatment Compounds
Godavari Biorefineries Limited has successfully secured a patent from the Japan Patent Office for its application No. 2022-568620. The patent pertains to the use of specific compounds for treating viral infections by inhibiting V-ATPase activity in cells. This grant strengthens the company's intellectual property portfolio in Japan and validates its research capabilities in the antiviral therapeutics space. While the immediate revenue impact is not specified, it enhances the company's long-term competitive positioning in global biochemical markets.
Key Highlights
Japan Patent Office granted patent No. 2022-568620 titled 'Use of Compounds for Treating Viral Infections'
The invention focuses on inhibiting V-ATPase activity in cells to treat viral infections
Strengthens global intellectual property protection and adds value to the antiviral therapeutics portfolio
The disclosure was made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
👀 What to Watch
Investors should monitor the company's progress in commercializing these patented compounds or potential licensing deals in the Japanese market. This development highlights the company's R&D strength beyond traditional biorefining.
Godavari Biorefineries Q3 PBT Jumps 152% to ₹21.4 Cr; EBITDA Margins Expand to 9.8%
Godavari Biorefineries reported a strong Q3 FY26 with Profit Before Tax (PBT) surging 152% YoY to ₹21.4 crores, despite modest revenue growth of 2.5%. The company achieved significant margin expansion, with EBITDA margins rising 97 bps to 9.8%, supported by a 48% reduction in finance costs and a better product mix in bio-based chemicals. Management highlighted a ₹325 crore capex plan through FY29, aimed at tripling EBITDA by focusing 75% of investment on high-margin chemicals. The consumer brand 'Jivana' also hit a milestone, crossing ₹100 crores in revenue for the 9-month period.
Key Highlights
Q3 PBT before exceptional items grew 152.2% YoY to ₹21.4 crores driven by operating leverage.
EBITDA increased by 13.8% to ₹45.1 crores with margins expanding to 9.8%.
Finance costs declined by 48% YoY, reflecting improved cash flows and balance sheet strengthening.
Bio-based chemicals EBITDA margin improved significantly to 7.7% from 4.5% in the previous year.
Consumer brand 'Jivana' achieved a revenue milestone of ₹100 crores during 9M FY26.
👀 What to Watch
Investors should focus on the company's transition toward high-margin specialty chemicals and its goal to triple EBITDA by FY29. Monitor the commissioning of the delayed grain-based distillery in Q1 FY27 as a key catalyst for the ethanol segment.
Godavari Biorefineries Q3 PBT Surges 152% YoY to ₹21.4 Cr; Debt Repayment Slashes Finance Costs
Godavari Biorefineries reported a 2.5% YoY growth in total income to ₹461.9 crore for Q3 FY26, while PBT (before exceptional items) jumped 152% to ₹21.4 crore. A significant driver was the 46% reduction in finance costs following the repayment of ₹240 crore in debt using IPO proceeds. The Bio-based Chemicals segment saw a 76.7% EBITDA growth, driven by a higher mix of specialty chemicals which now constitute 62% of the segment. However, the Ethanol segment faced a 23.6% revenue decline during the quarter due to seasonal and regulatory factors.
Key Highlights
Q3 PBT (before exceptional items) rose 152.3% YoY to ₹21.4 crore, supported by a 13.8% increase in EBITDA.
Finance costs dropped 46% YoY to ₹10.2 crore after repaying ₹240 crore of term debt via IPO proceeds.
Specialty chemicals now contribute 62% of Bio-based Chemicals revenue, up from 54% in the previous year.
A new 200 KLPD grain/maize distillery is on track for commissioning in Q1 FY27 to diversify feedstock.
Exceptional expense of ₹7.9 crore recognized in Q3 due to new labor law implementations.
👀 What to Watch
Investors should monitor the commissioning of the new distillery in Q1 FY27 and the continued margin expansion in the specialty chemicals segment. The significant reduction in interest burden improves the bottom-line outlook despite volatility in the ethanol segment.
Godavari Biorefineries Q3 PAT Rises 43% to ₹8.25 Cr; 9M Losses Narrow Significantly
Godavari Biorefineries reported a 43.2% YoY increase in consolidated Profit After Tax (PAT) for Q3 FY26, reaching ₹8.25 crore. Revenue from operations grew slightly to ₹459.85 crore, while the company saw a significant reduction in finance costs, which dropped to ₹10.21 crore from ₹18.85 crore YoY. For the nine-month period ended December 2025, the company narrowed its consolidated loss to ₹49.36 crore from a loss of ₹95.34 crore in the previous year. The company also issued a correction regarding a deferred tax entry in its nine-month results, clarifying it as Nil.
Key Highlights
Q3 FY26 PAT increased by 43.2% YoY to ₹8.25 crore from ₹5.76 crore in Q3 FY25.
Finance costs for the quarter significantly reduced by 45.8% YoY to ₹10.21 crore.
9M FY26 revenue from operations grew 10.3% YoY to ₹1,423.84 crore.
Consolidated loss for 9M FY26 narrowed substantially to ₹49.36 crore from ₹95.34 crore YoY.
Profit before exceptional items and tax for Q3 FY26 stood at ₹21.37 crore compared to ₹8.47 crore in the same quarter last year.
👀 What to Watch
The company is showing strong signs of a turnaround with improving quarterly profitability and a sharp reduction in interest expenses. Investors should watch for continued debt reduction and the impact of exceptional items on the bottom line in upcoming quarters.
Godavari Biorefineries Q3 PAT Rises 43% YoY to ₹8.25 Cr; Revenue Up 3%
Godavari Biorefineries reported a consolidated revenue of ₹459.85 crore for Q3 FY26, a 2.8% increase compared to ₹447.27 crore in the same quarter last year. The company's net profit for the quarter surged by 43.2% YoY to ₹8.25 crore, up from ₹5.76 crore in Q3 FY25. On a nine-month basis, while the company remains in a net loss of ₹49.36 crore, this is a significant improvement from the ₹95.34 crore loss reported in the previous year's corresponding period. A notable positive is the sharp reduction in finance costs, which dropped to ₹10.21 crore in Q3 FY26 from ₹18.85 crore in Q3 FY25.
Key Highlights
Q3 FY26 Revenue from operations grew 2.8% YoY to ₹459.85 crore.
Net Profit (PAT) for the quarter increased 43.2% YoY to ₹8.25 crore from ₹5.76 crore.
Finance costs saw a sharp decline of 45.8% YoY, falling to ₹10.21 crore in Q3 FY26.
9M FY26 losses narrowed significantly to ₹49.36 crore compared to a loss of ₹95.34 crore in 9M FY25.
The company reported an exceptional item expense of ₹7.88 crore during the current quarter.
👀 What to Watch
Investors should view the quarterly turnaround and significant reduction in finance costs as positive indicators of improving operational health. However, caution is advised as the company is still recovering from heavy losses on a cumulative nine-month basis.
